Congressman Tom Kean, who represents New Jersey’s 7th district in the U.S. Congress, recently addressed several topics on his official Twitter account, including concerns over foreign acquisitions in the biotech sector, local industry engagement, and community safety initiatives.
On November 3, 2025, Kean expressed apprehension regarding foreign business practices amid political turmoil: “A foreign company is blatantly exploiting the Democrats’ government shutdown to evade oversight by the Federal Trade Commission – and now they are moving to acquire a major U.S. biotech in the booming obesity-drug market, shutting down competition before it can grow. That kind https://t.co/9nku5cisd9”.
Later that day, Kean highlighted his visit to a local manufacturing facility operated by Kerry Group: “Last week I had the opportunity to tour Kerry Group’s manufacturing facility and Research & Development labs in Clark. Kerry Group is a global leader in the food and beverage industry, and their team of scientists is committed to developing great-tasting, nutritious, and https://t.co/AfYZXJ1nG7”.
On November 4, 2025, Kean discussed efforts to improve public safety through collaboration with law enforcement: “I hosted a crime prevention roundtable with local police & officials at every level of government to discuss how we can better support law enforcement and keep our neighborhoods safe. Collaboration is key to strengthening public safety in Warren County. https://t.co/ofOabQZVeh”.
Thomas Kean Jr., born in Livingston, New Jersey in 1968 and currently residing in Westfield, has represented New Jersey’s 7th District since 2023 after succeeding Tom Malinowski. Before his current role in Congress, he served in both the New Jersey General Assembly from 2001 to 2003 and the State Senate from 2008 to 2022. Kean graduated from Dartmouth College with a Bachelor of Arts degree.
